Introduction {#S1}
============

Leucine-rich repeat kinase 2 (LRRK2) is a large multidomain and dual enzymatic protein that exists intracellularly and predominantly as a dimer in its active form ([@B35]). LRRK2 has a number of purported functions, the most well studied of which include roles in the endolysosomal pathway and autophagy ([@B5]; [@B15]). Most significant, however, is the role that LRRK2 plays in human health. Mutations in *LRRK2* are a common genetic cause of Parkinson's disease (PD) ([@B8]). To date, at least seven missense mutations have been identified as causative in disease. These pathogenic mutations appear to cluster within the Roc-COR tandem (R1441C/G/H, N1437H, and Y1699C) and kinase (G2019S and I2020T) domains, implicating both GTPase and kinase activity in disease pathogenesis ([@B29]; [@B35]). Additional findings from GWAS have repeatedly linked variation at the *LRRK2* locus as an important risk factor in sporadic PD susceptibility ([@B62], [@B61]). Thus, LRRK2 represents a pleomorphic risk locus for PD pathogenesis as both a causative and risk-modifying factor.

Familial PD caused by *LRRK2* mutations (*LRRK2*-PD) generally develops as a late-onset autosomal dominant disorder and is thought to be driven by a toxic gain-of-function mechanism ([@B66]; [@B90]). A consensus view holds that elevated kinase activity underlies the pathogenic nature of LRRK2, as all causative mutations appear to enhance kinase activity, though GTPase activity seems to be required as well ([@B73]; [@B75]; [@B64]). Despite *LRRK2* mutations being one of the most common identifiable causes of PD, the vast majority of PD occurs via an unknown etiology. In spite of this, recent evidence suggests that LRRK2 activation (in the absence of mutation) may be present in sporadic PD ([@B52]). While being clinically indistinguishable from sporadic disease, *LRRK2*-PD frequently harbors neuropathological features synonymous with sporadic PD ([@B8]). These features include dopaminergic neurodegeneration in the midbrain along with the appearance of intraneuronal proteinaceous aggregates. These inclusions are generally associated with neurotoxicity, and inclusion burden in cortical and limbic regions is associated with the manifestation of cognitive and neuropsychiatric symptoms, a feature that spans both sporadic disease and *LRRK2*-PD ([@B1]; [@B10]; [@B26]; [@B74]). Thus, persuasive clinical findings infer that mutations in *LRRK2* might influence PD-associated pathology and provoke PD pathogenesis through mechanisms similar to those present in sporadic disease. While the application of LRRK2 pathobiology to idiopathic PD is alluring, it is critical that conserved pathologic features are reconciled with experimental evidence. Accordingly, the contribution of LRRK2 toward protein aggregation is of great interest and likely to be of therapeutic relevance.

A looming question in LRRK2 pathophysiology is whether protein aggregation is a primary or secondary effect of *LRRK2* mutations. Given the variety of neuropathology in *LRRK2*-PD, in many cases being diverse (i.e., co-pathology), it remains to be elucidated whether aggregation is simply resultant to LRRK2-mediated cellular dysfunction or whether pathogenic LRRK2 activity plays a more direct role in driving inclusion formation. Likewise, the requirement of protein aggregate substrates, such as α-synuclein or tau (reviewed in [@B60]), in mediating LRRK2-dependent neurodegeneration is far from clear. Notably, "pure" nigral degeneration in the absence of protein aggregate pathology, though rare, has been observed in *LRRK2*-PD ([@B24]; [@B76]). While it is possible that soluble oligomeric protein or other toxic species are still present in these atypical cases, the non-appearance of typical Lewy pathology composed of insoluble fibrillar α-synuclein, or neurofibrillary tangles composed of tau, suggest that inclusion pathology may be a by-product of *LRRK2*-PD pathogenesis rather than a required element. Even when present, it may be the case that the composition of protein aggregates in *LRRK2*-PD is wholly distinct from that of sporadic disease. Toward this concept, examination of α-synuclein derived from the *LRRK2*-PD brain was found to possess a divergent biochemical profile despite a comparable histopathological appearance to sporadic PD ([@B53]). Further, the range of pathological findings in the *LRRK2*-PD have been far from consistent. Though accruing post-mortem studies suggest that the common G2019S mutation appears to more faithfully produce typical Lewy pathology, examination of *LRRK2*-PD caused by other mutations has found substantial variation. Divergent pathology has even been observed in *LRRK2*-PD cases between affected members of the same family harboring an identical missense mutation ([@B90]). Thus, while the specific *LRRK2* mutation may have an impact on neuropathological variation, it appears likely that stochastic events may also play a role in the formation of protein aggregates. Though the apparent heterogeneity of *LRRK2*-PD neuropathology might at first suggest that inclusion formation is merely non-specific, accumulating evidence suggest a more selective and subtle impact of LRRK2 in facilitating protein aggregation. Toward addressing some of these questions, past and present genetic studies have granted some insight into the interplay of LRRK2 and the aggregate-prone proteins, α-synuclein and tau.

Common variation at the *SNCA* (encoding α-synuclein) and *MAPT* (encoding tau) loci have been associated with PD risk ([@B19]). Additionally, variation at these same loci has been implicated in affecting aspects of *LRRK2*-PD, such as the age of disease-onset ([@B36]; [@B27]; [@B25]; [@B9]). Thus, LRRK2, tau, and α-synuclein appear to converge in mysterious and seemingly complex ways in PD pathogenesis. Accordingly, elucidation of the interplay between LRRK2 and PD-associated proteins α-synuclein and tau is highly relevant to the application of LRRK2-targeted therapeutics in suppressing PD-associated neuropathology. Here, we will provide a concise review of current advances in understanding the contribution of LRRK2 toward protein aggregation in human studies and experimental models.

Protein Aggregation in Human *LRRK2*-PD {#S2}
=======================================

Substantial evidence supports a role for protein aggregation in the pathophysiology of PD ([@B59]). In sporadic disease, the presence of Lewy pathology composed of misfolded α-synuclein protein is a neuropathological hallmark. While predominantly restricted to the brainstem, Lewy pathology is believed to seemingly progress in a caudal to rostral fashion throughout the brain ([@B11]; [@B12]). The observation of Lewy pathology in surviving dopaminergic neurons of the substantia nigra has led to the hypothesis that inclusions are ultimately toxic, leading to the progressive loss of dopaminergic innervation of the striatum and associated hypokinetic motor phenotype ([@B69]). Further, an abundance of Lewy pathology in cortical and limbic brain regions has been associated with the clinical correlates of dementia and neuropsychiatric disease, respectively ([@B1]; [@B10]; [@B74]). Thus, the presence of α-synuclein aggregation appears to drive a heterogenous clinical phenotype by disrupting functional circuits in addition to driving progressive neurodegeneration.

Importantly, protein aggregation encompasses both sporadic and *LRRK2*-PD, suggesting a common pathologic basis of disease. However, whether neurodegeneration in sporadic and *LRRK2*-PD are equally dependent on protein aggregation, and whether all *LRRK2* mutations act through a common pathway is unknown. While progressive degeneration of dopaminergic neurons in the substantia nigra pars compacta remains the primary pathology, a feature that is universal across PD etiology, the nature, extent, and contribution of protein aggregation is far from clear. The majority of post-mortem neuropathological assessments have demonstrated that typical Lewy pathology is a predominant finding in *LRRK2*-PD ([@B8]). This is likely due to the overrepresentation of the G2019S mutation in post-mortem studies, as the G2019S mutation is by far the most common *LRRK2* mutation and appears to present with typical Lewy pathology. Pathological examination of *LRRK2*-PD brains harboring the G2019S mutation has identified typical, transitional, and diffuse Lewy pathology, tau and neurofibrillary tangle pathology, TDP-43 aggregates, ubiquitin inclusions, and even "pure" neurodegeneration without overt pathology ([@B66]; [@B90]; [@B8]; [@B85]; [@B80]; [@B46]). Thus, while α-synuclein aggregation appears to be the most prevalent finding, neuropathology in *LRRK2*-PD is pleomorphic. Aside from the G2019S mutation, a number of other post-mortem studies incorporating less common *LRRK2* mutations have discovered equally diverse pathological findings. Notably, several members of an affected family harboring the R1441C mutation were revealed to exhibit either Lewy pathology, neurofibrillary tangle pathology, or ubiquitin pathology ([@B90]). Ubiquitin inclusions in the absence of Lewy pathology was also observed in two patients with the Y1699C mutation ([@B90]). Intriguingly, no inclusions were detected in a patient with the R1441G mutation ([@B55]). Similarly, the I2020T mutation was demonstrated to induce nigral degeneration without significant Lewy pathology, though some cases were later found to harbor extensive brainstem tau pathology ([@B80]; [@B76]).

More recent observations have amplified the significance of tau pathology in *LRRK2*-PD. Indeed, a recent examination of post-mortem *LRRK2*-PD brains further illuminated the prominence of tau aggregation as a common pathologic substrate in *LRRK2*-PD ([@B32]). Though the sample size was limited, a larger proportion of *LRRK2*-PD brains were found to harbor tau pathology relative to α-synuclein pathology (100% vs. ∼64%). While phosphorylated α-synuclein (pSer129+) pathology was abundant in the substantia nigra, amygdala, hippocampus, and cingulate cortex, phosphorylated tau (AT8+) was more prominent in the amygdala, hippocampus, and entorhinal cortex. The regional mapping of each particular protein to a pathologic "territory" is plausibly in reference to a cell or tissue-dependent aspect of LRRK2 pathobiology. Given the preponderance of *LRRK2*-PD cases harboring mixed pathological features, future studies should make note of the regional distribution of pathology in dissecting mechanisms related to LRRK2 and protein aggregation. Returning to the findings of the above study, the midbrain was determined to be largely devoid of tau pathology, suggesting that while tau aggregation may be a typical pathologic feature in *LRRK2*-PD, the application of tau pathology to dopaminergic neuron loss remains ambiguous. The burden of tau pathology was, however, strongly associated with the level of α-synuclein pathology, reminiscent of evidence supporting the potential of tau and α-synuclein cross seeding ([@B28]). Neither tau nor α-synuclein burden was found to be associated with the level of amyloid-β pathology, further supporting a synergistic relationship between tau and α-synuclein rather than a general disruption in neuronal proteostasis. While a direct interaction between LRRK2 and tau or α-synuclein seems unlikely, it is notable that most regions harboring mixed pathology only rarely exhibited co-pathology within the same cell. It is interesting to hypothesize why some neuronal populations appear to foster one type of protein aggregate, while other populations of neurons another. As well, from an *in vivo* perspective, the requirement of tau or α-synuclein cross seeding in fostering LRRK2-dependent neurodegeneration is fascinating. Toward this concept, examining region-autonomous variation in LRRK2 biology may be a promising endeavor. While human studies have proven invaluable to our collective understanding of protein aggregation in *LRRK2*-PD, much of what is known regarding the mechanistic role of LRRK2 in driving protein aggregation and neuropathology has been garnered from animal models.

LRRK2 and Protein Aggregation in Animal Models {#S3}
==============================================

The identification of pathogenic mutations in the *LRRK2* gene has allowed for the generation of *LRRK2*-PD animal models. These models have provided valuable insight into the biology and pathobiology of LRRK2, though many key questions remain unanswered. While extensive work has been conducted in the development and characterization of these models, here, we will focus specifically on observations of protein aggregation and neuropathology. Toward this aim, experimental findings from traditional genetic, viral vector, and protein-based animal models will be discussed.

LRRK2 in Transgenic and Knockin Models {#S3.SS1}
--------------------------------------

Multiple pathogenic substitutions in the R1441 residue of the GTPase domain have been identified in *LRRK2*-PD and are associated with variable neuropathology ([@B90]). Some of the first LRRK2 animal models sought to examine the impact of mutations at this residue in the rodent brain ([Table 1](#T1){ref-type="table"}), and the development of R1441C knockin mice led to a primary identification of altered dopaminergic neurotransmission. However, the integrity of the nigrostriatal tract in R1441C knockin mice remained relatively unaffected ([@B77]). Furthermore, biochemical and histological assessment of these mice failed to detect any indications of tau, α-synuclein, or ubiquitin aggregation ([@B77]). In contrast, a BAC transgenic mouse line expressing human R1441G LRRK2 was found to harbor modest signs of tau pathology. Specifically, elevated protein levels of phosphorylated tau were identified in R1441G BAC mice relative to controls. In addition, neuritic inclusion pathology (AT8+) was observed in the cortex and striatum ([@B43]). While neurodegeneration was not observed in either of these genetic models, subtle alterations in the dopaminergic system were detected, along with a promising implication for involvement of tau.

###### 

LRRK2 in transgenic and knockin models.

  References   Model                                                                                             LRRK2 variant(s)            Neurodegeneration                                                                                        Pathology/Protein aggregation                                                                                                                                                                                           Additional findings
  ------------ ------------------------------------------------------------------------------------------------- --------------------------- -------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------
  [@B77]       LRRK2 knockin mice                                                                                R1441C                      Not observed                                                                                             No protein aggregation was observed, tau and α-synuclein protein levels were not altered                                                                                                                                Altered DA neurotransmission
  [@B43]       LRRK2 BAC Tg mice                                                                                 R1441G, Wild-type           Not observed                                                                                             R1441G mice harbored elevated protein levels of hyperphosphorylated tau, AT8+; axonal swellings and dystrophic neurites were observed in the dorsal striatum and piriform cortex α-synuclein protein was not assessed   R1441G mice displayed age-dependent motor activity deficits
  [@B45]       CamKIIα-tTA inducible LRRK2 Tg mice crossed with CamKIIα-tTA inducible α-synuclein A53T Tg mice   G2019S, Wild-type           Both G2019S and wild-type LRRK2 expression was found to exacerbate striatal and cortical neuronal loss   G2019S/A53T bigenic mice were found to have elevated levels of insoluble α-synuclein protein                                                                                                                            G2019S/A53T bigenic mice displayed enhanced astrogliosis and microglial activation
               LRRK2 knockout mice crossed with CamKIIα-tTA inducible α-synuclein Tg mice                        LRRK2^--/--^                LRRK2 deletion was shown to reduce the extent of striatal and cortical neuronal loss                     LRRK2 deletion was found to reduce the level of insoluble α-synuclein protein                                                                                                                                           LRRK2 knockout mice displayed a reduction in the level of astrogliosis and microglial activation
  [@B56]       LRRK2 BAC Tg mice                                                                                 G2019S, Wild-type           Not observed                                                                                             G2019S mice displayed mislocalization and increased phosphorylation of tau No abnormalities related to α-synuclein were detected                                                                                        Altered DA neurotransmission, G2019S mice display anxiety-like behaviors
  [@B42]       LRRK2 BAC Tg mice                                                                                 G2019S, Wild-type           Not observed                                                                                             α-synuclein and ubiquitin protein levels were not altered, wild-type mice displayed fewer PHF-1+/CP13+ cells in the dorsal striatum relative to control and G2019S mice                                                 Altered DA neurotransmission
  [@B71]       CMV-PDGFβ-driven LRRK2 Tg mice                                                                    G2019S, R1441C, Wild-type   Age-dependent DA neuronal loss was observed in G2019S mice                                               Abnormal phosphorylated tau and α-synuclein immunostaining was not detected                                                                                                                                             G2019S mice accumulate autophagic vacuoles
  [@B13]       CMV-PDGFβ-riven LRRK2 Tg mice                                                                     G2019S, Wild-type           Age-dependent DA neuronal loss was observed in G2019S mice                                               G2019S mice displayed elevated levels of phosphorylated tau in the substantia nigra No abnormalities related to α-synuclein were detected                                                                               G2019S mice displayed age-dependent motor activity deficits
  [@B17]       CMV-PDGFβ-driven LRRK2 Tg mice crossed with PrP-driven α-synuclein A53T Tg mice                   G2019S                      DA neuron loss was not altered in G2019S/A53T bigenic mice                                               G2019S/A53T bigenic mice exhibited a subtle increase in α-synuclein pathology in select brainstem regions                                                                                                               Premature lethality was not exacerbated in G2019S/A53T bigenic mice
               LRRK2 knockout mice crossed with PrP-driven α-synuclein A53T Tg mice                              LRRK2^--/--^                LRRK2 deletion did not alter DA neuron loss in A53T mice                                                 LRRK2 deletion yields a subtle reduction in α-synuclein pathology in select brainstem regions                                                                                                                           Behavioral phenotypes were not altered by LRRK2 deletion
  [@B33]       Thy1-driven LRRK2 Tg mice crossed with Thy1-driven α-synuclein A53T Tg mice                       G2019S, Wild-type           Not assessed                                                                                             G2019S/A53T bigenic mice did not exhibit altered levels of α-synuclein protein                                                                                                                                          G2019S/A53T bigenic mice did not display exacerbated microgliosis
  [@B4]        LRRK2 BAC Tg mice crossed with P301L tau (rTg4510) Tg mice                                        Wild-type                   Not assessed                                                                                             LRRK2/P301L-tau bigenic mice display increased accumulation and phosphorylation of insoluble tau along with enhanced cortical tau pathology                                                                             
  [@B88]       LRRK2 knockin mice                                                                                G2019S                      Not observed                                                                                             G2019S mice developed modest phosphorylated tau puncta and an increase in levels of phosphorylated tau protein, No differences in α-synuclein were detected                                                             Altered DA neurotransmission
  [@B58]       LRRK2 BAC Tg mice crossed with P301S tau (PS19 line) Tg mice                                      R1441G                      No exacerbation of neuronal loss was observed in R1441G/P301S-tau bigenic mice                           Tau aggregation and phosphorylation is not altered in R1441G/P301S-tau bigenic mice                                                                                                                                     Motor and memory deficits are not altered in R1441G/P301S-tau bigenic mice
  [@B87]       CamKIIα-tTA inducible LRRK2 Tg mice                                                               G2019S, G2019S/D1994A       Not observed                                                                                             G2019S mice displayed increased levels of insoluble α-synuclein protein in the cortex, striatum, and hippocampus, Tau protein was not assessed                                                                          G2019S mice exhibit amphetamine-induced behavioral deficits
  [@B48]       LRRK2 knockin mice                                                                                G2019S                      Not observed                                                                                             G2019S mice displayed elevated levels of phosphorylated α-synuclein protein in the striatum along with phosphorylated α-synuclein inclusions Tau protein was not assessed                                               G2019S mice exhibited dysfunction of DAT and VMAT2
  [@B86]       TH-tTA inducible LRRK2 Tg mice                                                                    G2019S, G2019S/D1994A       Age-dependent DA and NE neuronal loss was observed in G2019S mice                                        G2019S mice exhibited elevated levels of insoluble α-synuclein protein in the striatum and ventral midbrain Tau protein was not assessed                                                                                G2019S mice displayed age-dependent motor activity deficits
  [@B63]       CMV-PDGFβ-driven LRRK2 Tg mice crossed with P301S tau (PS19 line) Tg mice                         G2019S                      Not assessed                                                                                             G2019S/P301S-tau bigenic mice did not exhibit any alteration to tau protein levels, solubility, or phosphorylation state                                                                                                
               LRRK2 knockout mice crossed with P301S tau (PS19 line) Tg mice                                    LRRK2^--/--^                Not assessed                                                                                             LRRK2 deletion did not exhibit any alteration to tau protein levels, solubility, or phosphorylation state                                                                                                               

BAC, bacterial artificial chromosome; DA, dopaminergic; DAT, dopamine transporter; NE, noradrenergic; Tg, transgenic; TH, tyrosine hydroxylase; tTA, Tet-transactivator; VMAT2, vesicular monoamine transporter 2.

Subsequent genetic models sought to examine the impact of the G2019S mutation ([Table 1](#T1){ref-type="table"}). To date, a number of G2019S LRRK2 transgenic models have been developed, though findings have been mixed. Melrose et al. found that human G2019S LRRK2 BAC transgenic mice displayed phosphorylated tau inclusions (CP13+, 12E8+) in cortical and limbic brain regions at advanced ages (18--24 month) ([@B56]). Human wild-type LRRK2 BAC mice were also examined in this study and found to harbor tau pathology. However, in the wild-type LRRK2 line, tau pathology was primarily restricted to the hippocampus and to a much lesser burden than in G2019S mice. Notably, neither background was found to exhibit any apparent α-synuclein pathology. Similar to the R1441C knockin model, these mice also displayed abnormal dopaminergic neurotransmission, furthering support for a common pathogenic role in modulating synaptic function ([@B56]). While Melrose et al. found an additive effect of the G2019S mutation on tau phosphorylation, a separate study assessing a different mouse G2019S LRRK2 BAC transgenic model failed to detect any alterations ([@B42]; [@B56]). In contrast, accumulation of phosphorylated tau inclusions (PHF1+, CP13+) was not significantly elevated relative to control mice ([@B42]). While a number of factors might explain this discrepancy, including variation in strain background, or transgene copy number and/or genomic integration site, it is notable that neither model exhibited neurodegeneration of midbrain dopaminergic neurons ([@B42]; [@B56]).

Despite the lack of overt neurodegeneration in these early LRRK2 mouse models, although exhibiting modest neuropathologic phenotypes, parallel efforts developed a number of additional models focused on selectively boosting transgene expression within dopaminergic neurons of the substantia nigra ([Table 1](#T1){ref-type="table"}). While some of these models were successful in provoking dopaminergic neurodegeneration, the impact of protein aggregation in many of these models was generally not assessed or simply not detected ([@B71]; [@B13]; [@B78]; [@B47]). In one of these studies, transgenic mice expressing human G2019S LRRK2 under control of a CMV-enhanced human PDGFβ promoter were found to have an age-dependent (12--16 months) loss of dopaminergic neurons in the substantia nigra relative to controls expressing human wild-type LRRK2 from the same promoter ([@B13]). While no changes in α-synuclein or ubiquitin protein levels were observed, a nearly two-fold increase in phosphorylated tau (AT8+) was detected in the substantia nigra of G2019S LRRK2 mice ([@B13]). Unfortunately, the requirement of tau as a necessary pathologic substrate for neurodegeneration in this model was not determined. In a separate study, the G2019S mutation was expressed throughout the mouse forebrain under an inducible CamKIIα-tTA (Tet-transactivator) conditional expression system ([@B87]). This study also examined a kinase-inactive variant, G2019S/D1994A LRRK2, under the same expression system ([@B87]). While dopaminergic neurodegeneration was not observed with this approach, a substantial increase in the level of insoluble α-synuclein was detected in select forebrain regions of G2019S LRRK2 mice but not in G2019S/D1994A LRRK2 mice ([@B87]). However, a similar approach examining G2019S and G2019S/D1994A LRRK2 mutations under a TH-tTA conditional expression system discovered robust age- and kinase-dependent neurodegeneration coupled with an increase in the levels of insoluble α-synuclein ([@B86]).

In order to examine the G2019S mutation under more physiologic conditions, more recent studies have utilized G2019S LRRK2 knockin mice. While G2019S LRRK2 BAC transgenic mice previously displayed alterations in tau phosphorylation, [@B88] found that G2019S knockin mice failed to exhibit, similarly, significant changes. However, these mice did harbor modest pathology upon examination at advanced age (18 months). Cytoplasmic accumulation of phosphorylated tau (pSer202+) was observed, including some puncta formation and neuritic pathology ([@B88]). More readily apparent were deficits in striatal dopamine release and altered mitochondrial dynamics, again supporting synaptic alterations as an early sign of LRRK2 pathogenicity ([@B88]). In a separate study, G2019S LRRK2 knockin mice were found to exhibit a two-fold increase in the level of phosphorylated α-synuclein (pSer129) in the striatum ([@B48]). This finding was coupled with histological evidence of striatal α-synuclein inclusions. Importantly, both of these findings were age-dependent (12 months) ([@B48]). In a follow-up study, primary neuronal cultures generated from G2019S knockin mice were found to exhibit elevated levels of both phosphorylated tau (AT8+) and insoluble α-synuclein ([@B72]). Remarkably, administration of a LRRK2 kinase inhibitor was demonstrated to reverse the effect of the G2019S mutation on altered α-synuclein solubility, though the effect of kinase inhibition on tau phosphorylation was not determined ([@B72]). Certain species of α-synuclein and tau are thought to synergistically interact, and experimental evidence suggest that α-synuclein and tau are able to cross seed ([@B44]). While the finding of alterations to both α-synuclein and tau in a LRRK2 model are intriguing, the process by which this occurs may not necessarily be linear, and subsequent studies should address this concern.

While the collective findings from LRRK2 genetic animal models have not fully clarified the impact of LRRK2 on protein aggregation, the use of LRRK2 mice in a cross breeding approach has allowed for an alternative strategy in dissecting this relationship ([Table 1](#T1){ref-type="table"}). One of the first *in vivo* studies examining a potential interaction between LRRK2 and α-synuclein found that crossing inducible transgenic mice lines expressing human LRRK2 (either wild-type or G2019S) and A53T α-synuclein led to an increase in the burden of α-synuclein pathology ([@B45]). The mouse lines used in this study were generated using the CamKIIα-tTA conditional expression system, with transgene expression being restricted to the forebrain. While both LRRK2 lines independently were without phenotype, crossing either line with A53T mice had an additive effect on the level of cortical α-synuclein pathology. Intriguingly, A53T mice were also crossed with *LRRK2* knockout mice and a dramatic reduction in the burden of α-synuclein pathology was observed. Taken together, these findings first suggested that LRRK2 may be involved in the progression of α-synuclein neuropathology ([@B45]). Other studies examining the interaction of LRRK2 and α-synuclein have suggested that the impact of LRRK2 on protein aggregation may be more complex. In two related studies, distinct human mutant α-synuclein transgenic mouse models with predominant hindbrain pathology were found to have no pathological interaction with LRRK2 transgenic or knockout mice ([@B17]; [@B33]). It is possible that the discrepancy between these two studies and the former result from a regionally-restricted interaction between LRRK2 and α-synuclein, with greater potential for interaction in the forebrain where LRRK2 expression is enriched ([@B7]; [@B34]; [@B84]).

Similar to the potential interaction between LRRK2 and α-synuclein, a pathologic interplay between LRRK2 and tau has also been pursued using a cross breeding approach ([Table 1](#T1){ref-type="table"}). A human wild-type LRRK2 BAC transgenic mouse line crossed with inducible transgenic tau mice (expressing human P301L mutant tau under a CamKIIα-tTA conditional expression system) was shown to enhance cortical tau aggregation and increase tau phosphorylation (AT8+, CP13+, MC1+) ([@B4]). In contrast, a human R1441G LRRK2 BAC transgenic mouse line crossed with human P301S tau mice (driven by the mouse prion promoter, PrP) found no significant interaction ([@B58]). While the P301S tau mice used in this study developed widespread tau pathology, no additional alterations in tau aggregation or phosphorylation were identified in these bigenic mice ([@B58]). Similarly, modest hippocampal neuron loss specific to the P301S tau mouse background was not exacerbated by mutant LRRK2 ([@B58]). As this study did not generate P301S tau/LRRK2 knockout mice, it was not clear whether tau pathology was dependent on endogenous LRRK2 activity. However, a subsequent study was able to address this question. Nguyen et al. crossed the same PrP-P301S tau mice with either LRRK2 knockout or human G2019S transgenic mice (under the CMVe-PDGFβ promoter) ([@B63]). Neither genetic deletion of LRRK2 nor pathogenic mutation altered tau protein levels, solubility, or phosphorylation state. In addition, histopathological assessment of these mice found no interaction between tau pathology and LRRK2 genotype ([@B63]).

LRRK2 in Viral Vector-Based Models {#S3.SS2}
----------------------------------

Additional evidence supporting the involvement of LRRK2 in protein aggregation, propagation, and toxicity has come from the implementation of viral vectors in rodent models ([Table 2](#T2){ref-type="table"}). Importantly, the use of viral vectors offers several advantages over traditional genetic models. First, viral vector delivery offers spatiotemporal control of gene expression and avoids the potential confounding effects of developmental compensation. As well, higher levels of transgene expression are likely attainable when using this approach. In a practical sense, viral vectors may be applied across multiple genetic lines, amplifying the utility of viral vectors toward understanding disease-relevant interactions. Large-capacity viral vectors carrying full-length human LRRK2 have been used to uncover the impact of LRRK2 overexpression and pathogenic mutations on nigrostriatal pathway integrity ([Table 2](#T2){ref-type="table"}).

###### 

LRRK2 in viral vector-based models.

  References   Model                                                                                                               LRRK2 variant(s)                   Neurodegeneration                                                                                                                 Pathology/Protein aggregation                                                                                                                                                                                                                     Additional findings
  ------------ ------------------------------------------------------------------------------------------------------------------- ---------------------------------- --------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -----------------------------------------------------------------------------------------------
  [@B39]       Intrastriatal delivery of HSV vectors expressing LRRK2 in mice                                                      G2019S, Wild-type, G2019S/D1994A   DA neuronal loss was observed in a kinase-dependent manner with greater loss observed with the G2019S vector                      Not assessed                                                                                                                                                                                                                                      Non-selective LRRK2 kinase inhibitor treatment was demonstrated to attenuate DA neuronal loss
  [@B22]       Intrastriatal delivery of Ad5 vectors expressing LRRK2 in rats                                                      G2019S, Wild-type                  DA neuronal loss was observed in rats injected with the G2019S vector                                                             Phosphorylated tau inclusions were transiently observed in the substantia nigra α-synuclein and ubiquitin protein abnormalities were not detected                                                                                                 
  [@B18]       Intranigral delivery of AAV2/1 vector expressing WT α-synuclein in LRRK2 knockout rats                              LRRK2^--/--^                       DA neuron loss was ameliorated in LRRK2 knockout rats                                                                             LRRK2 deletion did not alter levels of α-synuclein protein                                                                                                                                                                                        LRRK2 deletion was also demonstrated to protect against LPS-induced pathology
  [@B79]       Intrastriatal delivery of Ad5 vectors expressing LRRK2 in rats                                                      G2019S, G2019S/D1994N, Wild-type   Loss of TH+ fiber density in the striatum was found to be independent of LRRK2 kinase activity, DA neuron loss was not observed   Ubiquitin+ inclusions and altered neurofilament distribution were observed in the striatum Tau and α-synuclein protein abnormalities were not detected                                                                                            
  [@B16]       Intranigral delivery of AAV2/1 vector expressing WT α-synuclein in LRRK2 BAC Tg rats                                G2019S                             DA neuron loss was shown to be exacerbated in G2019S rats                                                                         Not assessed                                                                                                                                                                                                                                      LRRK2 kinase inhibitor treatment was demonstrated to attenuate DA neuron loss
  [@B2]        Intranigral delivery of AAV2/5 vector expressing A53T α-synuclein in LRRK2 knockout rats                            LRRK2^--/--^                       Aberrant STN burst firing activity was ameliorated in LRRK2 knockout rats                                                         α-synuclein phosphorylation state was not altered across all conditions                                                                                                                                                                           STN burst firing activity was also corrected by LRRK2 kinase inhibition (PF360)
  [@B65]       Intranigral delivery of AAV2/9 vector expressing α-synuclein in LRRK2 knockin mice                                  G2019S                             No additive effect on DA neuron loss was observed in the G2019S mice                                                              α-synuclein pathology was found to be elevated in the substantia nigra of G2019S mice                                                                                                                                                             
  [@B63]       Intrahippocampal delivery of AAV2/6 vector expressing either wild-type or P301S mutant tau in LRRK2 Tg mice         G2019S                             Hippocampal neuron loss was not altered in G2019S mice                                                                            Hippocampal tau pathology was not altered in G2019S mice                                                                                                                                                                                          G2019S was found to enhance the neuronal transmission of wild-type tau
               Intrahippocampal delivery of AAV2/6 vector expressing either wild-type or P301S mutant tau in LRRK2 knockout mice   LRRK2^--/--^                       Hippocampal neuron loss was not altered in LRRK2 knockout mice                                                                    Hippocampal tau pathology was not altered in LRRK2 knockout mice                                                                                                                                                                                  Endogenous LRRK2 was found to be dispensable for the neuronal transmission of wild-type tau
  [@B38]       Intrastriatal delivery of HC-AdV expressing LRRK2 in mice                                                           G2019S, D1994N                     DA neuron loss was not observed, but modest striatal cell loss was observed with the G2019S vector in aged mice                   No evidence of ubiquitin, tau, or α-synuclein pathology was observed                                                                                                                                                                              Glial LRRK2 expression was found to contribute to neuroinflammation
  [@B57]       Intrastriatal delivery of CAV-2 vectors expressing LRRK2 in *M. murinus* (non-human primate)                        G2019S                             DA neuron loss was observed with both G2019S and GFP control vectors                                                              Phosphorylated tau and α-synuclein pathology were observed with the G2019S vector                                                                                                                                                                 
  [@B64]       Intrastriatal delivery of Ad5 vectors expressing LRRK2 in rats                                                      G2019S, Wild-type, G2019S/K1906M   DA neuron loss was observed in a kinase-dependent manner with greater loss observed with the G2019S vector                        Phosphorylated tau inclusions were observed in the substantia nigra across all vectors, APP+ inclusions and degenerative neuritic changes in the striatum were observed with the G2019S vector Changes to α-synuclein protein were not detected   LRRK2 kinase inhibitor (PF360) treatment was demonstrated to attenuate DA neuron loss
  [@B20]       Intranigral delivery of CAV-2 vectors expressing LRRK2 in *M. fascicularis* (non-human primate)                     G2019S                             DA neuron loss was observed in both G2019S and GFP control vectors                                                                Phosphorylated tau pathology was observed with both the G2019S and GFP control vectors with a modest increase in select regions for the G2019S vector α-synuclein protein was not assessed                                                        

AAV, adeno-associated virus; Ad5, human adenovirus serotype 5; BAC, bacterial artificial chromosome; CAV-2, canine adenovirus serotype 2; DA, dopaminergic; HSV, herpes simplex virus; LPS, lipopolysaccharide; Tg, transgenic; WT, wild-type.

In a herpes simplex virus (HSV) vector mouse model, either human wild-type, G2019S, or G2019S/D1994A LRRK2 variants (kinase-inactive) were delivered via intrastriatal injection ([@B39]). Using this approach, modest dopaminergic neuronal loss was observed with the wild-type variant with significantly greater loss with the G2019S variant. Concurrently, the kinase-inactive variant did not induce any observable loss and concurrent administration of early yet non-selective LRRK2 kinase inhibitors was shown to attenuate neurodegeneration in this model. Accordingly, these findings support the importance of functional kinase activity in mediating dopaminergic neurodegeneration. Unfortunately, protein aggregation was not assessed in this study so it is not clear how tau or α-synuclein might be involved with LRRK2 delivered via HSV vectors.

Another study examining human LRRK2 utilized human adenoviral vectors (Ad5) driven by a neuronal-specific synapsin-1 promoter and found similar findings to the HSV model ([@B22]). In this approach, intrastriatal delivery of Ad5 carrying G2019S LRRK2 induced robust neurodegeneration in the substantia nigra of adult rats, while no effect was observed with the wild-type LRRK2 or GFP vectors. Intriguingly, transient induction of neuritic inclusions was observed in the substantia nigra with both wild-type and G2019S vectors. These inclusions exhibited positive immunostaining for phosphorylated tau (AT8+) but not for α-synuclein ([@B22]). Following these initial findings, a second study examined the impact of the Ad5-LRRK2 on striatal pathology ([@B79]). Intraneuronal ubiquitin-positive inclusions were observed in the striatum of rats injected with the G2019S LRRK2 vector, but not with a G2019S/D1994N vector. As well, degenerative neuritic changes and altered phosphorylated neurofilament distribution were observed in the striatum in a kinase-dependent fashion ([@B79]). Unfortunately, the G2019S/D1994N mutation was shown to alter LRRK2 protein stability, partly confounding the validity of this synthetic inactive mutation in determining kinase-dependency. However, an additional study performing intrastriatal injection of Ad5-LRRK2 vectors at a higher viral titer in rats utilized an alternative stable kinase-inactivating mutation, G2019S/K1906M ([@B64]). In this study, phosphorylated tau inclusions were detected in the substantia nigra across all LRRK2 variants, suggesting that the effect is not specific to the G2019S mutation or kinase activity ([@B64]). Concurrently, biochemical analysis determined that tau protein levels, phosphorylation state, and solubility were not altered in response to Ad5-LRRK2 vectors ([@B64]). Additionally, ubiquitin-positive inclusions in the striatum did not appear to be dependent on kinase activity and none of the LRRK2 vectors induced detectable α-synuclein pathology. However, in this study, the G2019S LRRK2 vector alone induced APP-positive axonal inclusions and degenerative neuritic changes in the striatum ([@B64]). In a separate study, high-capacity adenoviral vectors (HC-AdV) expressing G2019S or G2019S/D1994N LRRK2 variants from a ubiquitous CAG promoter were delivered to the striatum of mice ([@B38]). In this instance, modest age-dependent neuroinflammation and vacuolization of striatal white fiber tracts was induced by G2019S LRRK2 only in old animals, but protein aggregation was not detected ([@B38]). Outside of rodents, a helper-dependent canine adenovirus type 2 (CAV-2) vector expressing human wild-type or G2019S LRRK2 was utilized in a non-human primate model, *Microcebus murinus* ([@B57]). In this model, nigral neurodegeneration was equivalently observed with both LRRK2 variants and with a GFP control, making interpretation of this LRRK2 model challenging, although an increase in α-synuclein and tau phosphorylation (pSer129-αSyn+ and pSer396-tau+, respectively) was identified due to the G2019S variant ([@B57]). An additional study assessing CAV-2-LRRK2 vectors in macaques, similarly, found an elevation of phosphorylated tau (PHF+) immunostaining in the substantia nigra of G2019S LRRK2-injected animals ([@B20]).

In contrast to viral vectors delivering LRRK2, viral vectors have also been used to introduce α-synuclein overexpression in neuronal populations of interest. Moreover, these vectors have proven to reliably induce neurodegeneration indicative of α-synuclein-dependent toxicity ([@B81]). In order to investigate the contribution of LRRK2 toward protein aggregation and neuropathology, α-synuclein viral vectors have been introduced into LRRK2 rodent models in an approach that mimics the generation of bigenic models discussed previously. Toward this, an AAV2/1 vector delivering human wild-type α-synuclein to the substantia nigra of adult rats was shown to induce ∼30% loss of dopaminergic neurons ([@B18]). Remarkably, when the same vector was introduced in *LRRK2* knockout rats, the neurodegenerative phenotype was ameliorated. While it was difficult to assess the extent of α-synuclein pathology in this model due to neuronal loss, the level of α-synuclein pathology was shown to inversely correlate with cell loss ([@B18]). In a subsequent study, AAV2/1-α-synuclein was delivered to the substantia nigra of G2019S LRRK2 BAC transgenic rats ([@B16]). Here, dopaminergic cell loss was determined to be significantly increased in the G2019S LRRK2 rats relative to control animals, and importantly, this effect was found to be kinase-dependent as pharmacologic kinase inhibition reversed the effect ([@B16]).

Use of an AAV2/5-α-synuclein vector delivered to the substantia nigra of rats was shown to induce aberrant neuronal firing activity in the subthalamic nucleus ([@B2]). Intriguingly, this pathologic effect was not present in *LRRK2* knockout rats and was reversed in wild-type rats following administration of a LRRK2 kinase inhibitor ([@B2]). However, a later study found that long-term administration of a LRRK2 kinase inhibitor failed to protect against this abnormal α-synuclein-mediated neuronal dysfunction in rats ([@B3]). Another study examined the impact of the G2019S mutation on virally mediated α-synuclein pathology using a more physiologically relevant model. Using G2019S LRRK2 knockin mice, along with wild-type controls, [@B65] found that stereotactic injection of AAV2/9 vectors expressing human A53T α-synuclein was sufficient to induce ∼50% loss of dopaminergic neurons in the substantia nigra. However, no additive neurodegenerative effect was conferred by the G2019S mutation in the knockin model. Rather, G2019S knockin mice were found to exhibit a nearly two-fold increase in the level of nigral α-synuclein pathology (as measured by pSer129+ immunostaining) ([@B65]). This study also sufficiently characterized the observed α-synuclein pathology as resistant to proteinase-K treatment, indicative of fibrillar aggregates ([@B65]). While these findings suggest that LRRK2 may, in part, mediate the neurodegenerative phenotype of α-synuclein, a separate study identified LRRK2 activation via proximity ligation assays in the substantia nigra of rats following intranigral injection of AAV2/1 vector expressing human wild-type α-synuclein ([@B52]). Thus, while overexpression of LRRK2 via viral vector delivery is not generally sufficient to induce α-synuclein pathology in the face of neurodegeneration, the reverse seems to be true in that virally-mediated α-synuclein pathology may be potentiated by LRRK2 activity.

While less is known about the function of LRRK2 activity on virally-induced tau pathology, alterations to tau biology have been a common observation in LRRK2 animal models. The generation of bigenic mice examining the impact of LRRK2 genotype in mutant tau transgenic mice model previously failed to detect substantial changes to tau ([@B63]). However, additional experimentation suggests that LRRK2 genotype may alter other aspects of virally-mediated tau pathology. Utilizing AAV2/6 vectors to deliver human P301S tau via intrahippocampal injection, Nguyen et al. compared LRRK2 knockout and G2019S LRRK2 transgenic mice ([@B63]). While P301S tau induced ample tau pathology in the hippocampus, LRRK2 genotype was not determined to alter the burden of tau pathology or hippocampal neuronal loss ([@B63]). In contrast, use of an AAV2/6 vector co-expressing human wild-type tau and a GFP reporter revealed an impact of LRRK2 genotype on the neuronal transmission of tau within defined hippocampal circuits ([@B63]). While endogenous LRRK2 was found to be dispensable for tau transmission, a two-fold increase in transmission to both ipsilateral and contralateral CA3 regions was observed in G2019S LRRK2 transgenic mice ([@B63]). Notably, this experiment found no evidence of tau aggregation or neurodegeneration following viral vector delivery of wild-type tau, suggesting that LRRK2 activity may instead serve to accelerate the spread of tau pathology from cell-to-cell within defined circuits.

LRRK2 in Protein-Based Models {#S3.SS3}
-----------------------------

Accumulating evidence from human and experimental animal studies supports the pathological transmission of α-synuclein and tau species in PD and other neurodegenerative diseases ([@B23]). Notably, both α-synuclein and tau pathology have been observed in fetal neural grafts of PD patients at autopsy ([@B37]; [@B40], [@B41]; [@B14]). While the mechanistic explanations surrounding the stereotypical spatiotemporal spread of tau and α-synuclein pathology remains uncertain, it is clear that protein aggregation is inducible across interconnected neuronal populations and in a sequential pattern. Experimental models have demonstrated the cell-to-cell release and uptake of toxic protein species ([@B83], [@B82]; [@B54]). Whether such direct transmission models are relevant to human disease still remains to be determined but understanding the progression of inclusion formation within the context of *in vivo* models is certain to be invaluable. The development of α-synuclein pre-formed fibrils (PFF) as an experimental tool has allowed for the examination of cell-to-cell transmission of α-synuclein and resulting induction of pathology ([@B50]; [@B83]; [@B21]; [@B70]; [@B67]). Importantly, PFF-induced α-synuclein inclusions recapitulate key features of human Lewy pathology. Direct delivery of α-synuclein PFFs into the rodent brain has provided a robust model in which to dissect mechanisms of protein misfolding, aggregation, and spread *in vivo*. While the advancement and implementation of tau PFFs *in vivo* have been more limited, both α-synuclein and tau have been used to further a mechanistic understanding of pathological aggregation in the mammalian brain.

The introduction of α-synuclein PFFs into LRRK2 rodent models has provided a robust system in which to determine how LRRK2 activity relates to the progression and propagation of α-synuclein aggregation as well as the impact of pathogenic LRRK2 activity on α-synuclein mediated neurodegeneration ([Table 3](#T3){ref-type="table"}). Importantly, inoculation with α-synuclein PFFs and subsequent induction of Lewy-like pathology has been demonstrated to be dependent on the presence of endogenous α-synuclein ([@B83]; [@B49]). Moreover, the level of pathologic burden across brain regions appears related to the regional variation in α-synuclein expression, such that brain regions associated with elevated levels of α-synuclein are associated with a greater severity of α-synuclein pathology while regions with lower levels of expression are associated with relative resistance to pathology ([@B30]). While the PFF model is less useful in determining the contribution of LRRK2 mutations toward the direct initiation of α-synuclein or tau pathology, other aspects of this model have proven instrumental. Notably, the PFF model has robustly demonstrated the importance of neural connectivity rather than area locality for the transmission of pathology, further supporting a cell-to-cell transmission mechanism in the progression of pathology ([@B30]). This feature is readily observed in the established rodent intrastriatal injection paradigm, in which the induction of α-synuclein pathology progressively accumulates in neuronal populations innervating the striatum. This observation is readily apparent in the substantia nigra, where progressive α-synuclein pathology peaks at 2--3 months following injection followed by modest neurodegeneration by 6 months ([@B49]; [@B68]). The PFF model thus allows for examination of the spatiotemporal spread of protein substrates coupled with insight into selective vulnerability of affected regions.

###### 

LRRK2 in protein-based models.

  References   Model                                                                               LRRK2 variant(s)   Neurodegeneration                                                 Pathology/Protein aggregation                                                             Additional findings
  ------------ ----------------------------------------------------------------------------------- ------------------ ----------------------------------------------------------------- ----------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------
  [@B82]       Intranigral delivery of PFF in LRRK2 BAC Tg rat                                     G2019S             Not observed                                                      G2019S rats exhibited increased α-synuclein inclusion burden in the substantia nigra      
  [@B89]       Intrastriatal delivery of PFF in mice treated with LRRK2 ASO                        Not Applicable     Administration of LRRK2 ASO reduced PFF-induced DA neuron loss    Administration of LRRK2 ASO reduced PFF-induced α-synuclein pathology                     
  [@B30]       Intrastriatal delivery of PFF in LRRK2 BAC Tg mice                                  G2019S             G2019S mice exhibited a modest increase in DA neuronal loss       G2019S mice displayed elevated α-synuclein pathology in select brain regions              G2019S mice demonstrated altered dynamics of pathological α-synuclein spread
  [@B31]       Intrastriatal delivery of PFF in mice treated with LRRK2 kinase inhibitor (MLi-2)   Not Applicable     MLi-2 administration did not alter PFF-induced DA neuronal loss   MLi-2 administration did not alter PFF-induced α-synuclein pathology                      MLi-2 administration did not impact the PFF-induced behavioral profile
  [@B6]        Intrastriatal delivery of PFF in LRRK2 BAC Tg mice                                  G2019S             G2019S mice demonstrated enhanced DA neuronal loss                G2019S mice displayed an increased α-synuclein inclusion burden in the substantia nigra   G2019S mice injected with PFF exhibited motor activity deficits and an altered neuroinflammatory profile

ASO, antisense oligonucleotide; BAC, bacterial artificial chromosome; DA, dopaminergic; PFF, preformed fibrils of α-synuclein; Tg, transgenic.

The implementation of the PFF model in comparative genetic mouse models has facilitated a greater understanding of how LRRK2 activity might alter the progression of pathology at the connectome level ([Table 3](#T3){ref-type="table"}). In a recent study by Henderson et al., regional variation in the burden of α-synuclein pathology was observed in G2019S LRRK2 BAC transgenic mice compared to non-transgenic controls (following intrastriatal PFF injection), such that G2019S mice displayed both higher and lower levels of α-synuclein pathology across distinct brain regions ([@B30]). Intriguingly, a significant increase in the burden of α-synuclein pathology was observed in the cortex of G2019S mice. Robust LRRK2 transgene expression is present in the cortex of G2019S mice, suggesting that heightened LRRK2 levels may potentiate α-synuclein pathology in this region. Indeed, G2019S mice were shown to harbor a greater burden of pathology in regions that were resilient in non-transgenic mice. In terms of dopaminergic neurodegeneration, G2019S mice displayed a modest increase in nigral neuronal loss which was reflective of elevated α-synuclein pathology in the substantia nigra. Additional studies have sought to identify whether LRRK2 is required for α-synuclein transmission and neurodegeneration in the PFF model. Administration of MLi-2, a selective LRRK2 kinase inhibitor, in mice inoculated with α-synuclein PFFs demonstrated no significant impact on the induction of α-synuclein pathology in several regions of interest or alterations in dopaminergic cell loss in the substantia nigra ([@B31]). While these findings suggest an additive, but not critical, role for mutant LRRK2 in promoting α-synuclein pathology *in vivo*, other studies have produced contrasting results. Toward this, administration of antisense oligonucleotides directed against LRRK2 were found to reduce α-synuclein inclusion burden and neurodegeneration in an α-synuclein PFF model ([@B89]). As well, primary neuronal cultures derived from either LRRK2 knockin or knockout mice were found to exhibit differential levels of α-synuclein aggregate pathology following PFF administration, with LRRK2 knockout playing a protective role ([@B51]).

Despite the mixed findings, several additional studies have noted either an acceleration or exacerbation of PFF-induced α-synuclein pathology in the context of the pathogenic G2019S mutation. While enhanced LRRK2 activity does not appear to enhance neuronal uptake of fibrils *in vitro*, it is possible that mutant LRRK2 impacts diverse biological processes that result in the potentiation of aggregation. Volpicelli-Daley et al. found that overexpression of G2019S LRRK2 in a BAC transgenic rat model increased the number of α-synuclein and ubiquitin-positive inclusions in the substantia nigra at 1 month following unilateral intranigral PFF injection ([@B82]). Likewise, [@B6] found that bilateral intrastriatal injection of α-synuclein PFF into G2019S LRRK2 BAC mice led to an exacerbation of phosphorylated α-synuclein aggregates across interconnected brain regions including the substantia nigra. While the effect of the G2019S mutation on protein aggregation was significant at 1, 3, and 6 months following PFF injection, the effect size was diminished over time. This observation supports that PFF-induced pathology may be subject to a thresholding effect, and, additionally, that LRRK2 may have both an immediate impact on the induction of pathology as well as longitudinal control of aggregate formation. Of interest, dopaminergic cell loss was more severe in the G2019S background, which could be resultant from the increased burden of aggregate pathology or from an intrinsic impact of G2019S LRRK2 on neuronal survival ([@B6]). In total, LRRK2 appears to subtlety modulate the burden of protein aggregate pathology ([Table 3](#T3){ref-type="table"}), though the mechanism by which this occurs remains to be fully uncovered.

Conclusion {#S4}
==========

Given the heterogenous pathological landscape of *LRRK2*-PD, it remains uncertain whether and how LRRK2 activity might impact the development of protein aggregate pathology. Although there is evidence for a potential interaction between LRRK2 and α-synuclein, or LRRK2 and tau, many studies in animal models have had conflicting results. This likely arises from variations in experimental approach and models, and further lack of understanding of LRRK2 biology. Even when an interaction is identified, the mechanisms by which LRRK2 induces, promotes, or accelerates aggregation or neurodegeneration are not well-defined. While some studies suggest that LRRK2 is not critical for the development of α-synuclein or tau pathology, the opposite paradigm still remains to be fully explored. Whether α-synuclein or tau are essential for mutant LRRK2-induced neuropathology has not been formally evaluated *in vivo*. Subsequent studies will clarify this interaction and seek to place the significance and interaction of LRRK2, α-synuclein, and tau within PD-associated neurodegenerative processes. Toward this aim, LRRK2 animal models have been critical in developing our current understanding of LRRK2 pathobiology and, along with technological refinements and advances in this area, they are poised to play a significant role in future mechanistic studies of LRRK2, including protein aggregation pathways.
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